(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 28.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.92%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Gossamer Bio's revenue in 2025 is $40,237,000.On average, 5 Wall Street analysts forecast GOSS's revenue for 2025 to be $8,402,168,264, with the lowest GOSS revenue forecast at $4,861,397,420, and the highest GOSS revenue forecast at $15,189,024,681. On average, 4 Wall Street analysts forecast GOSS's revenue for 2026 to be $6,046,505,155, with the lowest GOSS revenue forecast at $3,790,434,752, and the highest GOSS revenue forecast at $11,300,816,267.
In 2027, GOSS is forecast to generate $22,110,035,658 in revenue, with the lowest revenue forecast at $4,547,612,180 and the highest revenue forecast at $49,682,663,067.